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ABSTRACT In this study, we examined the relationships between anti-influenza vi-
rus serum antibody titers, clinical disease, and peripheral blood leukocyte (PBL)
global gene expression during presymptomatic, acute, and convalescent illness in 83
participants infected with 2009 pandemic H1N1 virus in a human influenza chal-
lenge model. Using traditional statistical and logistic regression modeling ap-
proaches, profiles of differentially expressed genes that correlated with active viral
shedding, predicted length of viral shedding, and predicted illness severity were
identified. These analyses further demonstrated that challenge participants fell into
three peripheral blood leukocyte gene expression phenotypes that significantly cor-
related with different clinical outcomes and prechallenge serum titers of antibodies
specific for the viral neuraminidase, hemagglutinin head, and hemagglutinin stalk.
Higher prechallenge serum antibody titers were inversely correlated with leukocyte
responsiveness in participants with active disease and could mask expression of pe-
ripheral blood markers of clinical disease in some participants, including viral shed-
ding and symptom severity. Consequently, preexisting anti-influenza antibodies may
modulate PBL gene expression, and this must be taken into consideration in the de-
velopment and interpretation of peripheral blood diagnostic and prognostic assays
of influenza infection.
IMPORTANCE Influenza A viruses are significant human pathogens that caused
83,000 deaths in the United States during 2017 to 2018, and there is need to under-
stand the molecular correlates of illness and to identify prognostic markers of viral
infection, symptom severity, and disease course. Preexisting antibodies against viral
neuraminidase (NA) and hemagglutinin (HA) proteins play a critical role in lessening
disease severity. We performed global gene expression profiling of peripheral blood
leukocytes collected during acute and convalescent phases from a large cohort of
people infected with A/H1N1pdm virus. Using statistical and machine-learning ap-
proaches, populations of genes were identified early in infection that correlated with
active viral shedding, predicted length of shedding, or disease severity. Finally, these
gene expression responses were differentially affected by increased levels of preex-
isting influenza antibodies, which could mask detection of these markers of conta-
giousness and disease severity in people with active clinical disease.
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Influenza A viruses (IAV) are a significant cause of morbidity and mortality. Annualestimates of death from seasonal IAV range up to 79,400 in the United States and
250,000 to 500,000 in industrial nations (1, 2). The 2009 H1N1 pandemic resulted in at
least 200,000 deaths globally, while the 1918 H1N1 pandemic resulted in 50 to 100
million deaths (3–5). IAV infection in humans is typically an acute, self-limited disease
associated with virus replication in the upper respiratory tract, which may progress to
lower respiratory tract involvement in more severe cases, including secondary bacterial
infections and pneumonia (6). Influenza illness typically presents with mild to moderate
symptoms, including rhinorrhea, dry cough, malaise, headache, and fever (6). The onset
of symptoms typically occurs after viral shedding begins; therefore, an infected person
can be contagious for 1 to 2 days prior to symptom onset. This creates a significant
challenge in limiting community spread using standard post-symptom onset diagnostic
testing. In addition, complicated disease typically occurs after the initial onset of mild
to moderate symptoms, making the task of early prediction and triage of patients who
will progress to severe disease difficult. Identifying pre- or early symptomatic markers
of infection, contagiousness, and disease severity is key to reducing morbidity and
mortality by offering new tools to reduce the spread of disease through early detection
and isolation of contagious individuals and early recognition of patients needing
treatment or monitoring for severe disease and complication.
A critical host determinant affecting infection, shedding, and disease severity is
preexisting influenza immunity, including both cellular immunity and anti-IAV antibod-
ies arising from previous viral infection and/or vaccination (7–14). While cellular immu-
nity and memory lymphocyte responses play essential roles in immunity to IAV, most
studies of protection have focused on serum antibodies against IAV proteins. The most
dominant IAV antigens are the surface glycoproteins hemagglutinin (HA) and neur-
aminidase (NA) (1). Many neutralizing antibodies bind to the head of the HA protein,
which are typically measured using an HA inhibition (HAI) assay. For IAV vaccine
development, a serum HAI antibody titer of 1:40 is the internationally accepted
standard of protection and was demonstrated to protect 50% of individuals from IAV
infection (15, 16). Recently, the role of non-HA head immunity has gained much
interest, including antibodies against the IAV NA protein and a more conserved stalk
(stem) region of the HA protein (17, 18). Previous studies using a human influenza A
viral challenge model have shown the relative importance of these three types of
antibody responses, and while antibodies against NA, HA head, and HA stalk are all
correlated with a reduction in length of shedding, only prechallenge antibodies against
NA were independently correlated with both a decreased length of shedding and
symptom severity (11, 12).
This study was undertaken to examine the relationship between peripheral immune
cell gene expression, clinical disease, and preexisting NA and HA serum antibody titer.
Global gene expression profiles of peripheral blood leukocytes (PBL) from 83 human
challenge study participants collected at 18 h, 42 h, 90 h, and 138 h after intranasal
inoculation with A/H1N1pdm IAV were compared with viral shedding, symptom
duration, symptom severity, and preexisting antibody levels. Using this approach,
we were able to identify three distinct expression phenotypes as early as 42 h
postinoculation and identify differentially expressed gene signatures at the pre- or
early symptomatic phase that were predictive of shedding duration and clinical
disease severity. This study shows the importance of preexisting antibodies against
viral NA (NAI), HA head (HAI), and HA stalk (HA-S) in modulating PBL gene
expression responses during human influenza viral challenge and identifies popu-
lations of genes that are predictive for disease severity and length of upper
respiratory tract viral shedding.
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RESULTS
Human influenza viral challenge model and participant cohort. PBLs were
collected for gene expression microarray analysis from 83 healthy volunteers inoculated
with 107 TCID50 of a GMP-manufactured wild-type 2009 pandemic H1N1 IAV (A/
H1N1pdm) in an established influenza viral challenge model (19). Previously published
study participant demographics, clinical data, and baseline NAI, HAI, and HA stalk
antibody titers are summarized in Table 1. A clinical study outcome denoted “mild-to-
moderate influenza disease” (MMID) (19), was used and defined as viral shedding
detected by clinical molecular testing, in addition to the onset of at least one acute
influenza-like illness symptom following intranasal challenge. The No MMID partici-
pants either had symptoms in the absence of viral shedding, asymptomatic shedding,
or neither symptoms nor shedding (Table 1).
Baseline PBL gene expression did not correlate with differential PBL gene
expression responses or clinical outcome following challenge. Expression microar-
rays were used to measure PBL global gene expression responses prior to viral
challenge (0 h) and at multiple time points 18 h, 42 h, 90 h, and 138 h during the acute
phase of IAV infection. Analysis of global preinfection gene expression profiles did not
show significant differentiation of participants based on study outcome (MMID or No
MMID), severity of illness (measured as maximum clinical symptom score), or length of
viral shedding (see Fig. S1A to C in the supplemental material). Baseline expression
levels of canonical antiviral response genes (20) did not show statistically significant
differences between MMID and No MMID participants (n 42) (Fig. S1D). Indeed,
comparison of global profiles of preexposure samples failed to identify statistically
significant gene expression differences between MMID and No MMID participants.
Early gene expression changes correlated with active viral shedding. Expression
values from each participant’s PBL sample collected postinfection (18 h, 42 h, 90 h, and
138 h) were normalized to their own preexposure time point (0 h). To identify genes
associated with active viral replication and shedding but independent of clinical
parameters, samples from participants that were positive for viral shedding in nasal
washes were compared by two-tailed t test to samples from participants without
evidence of shedding (see Tables S1 to S3 at https://systemsbiology.org/wp-content/
uploads/Walters-et-al-Supplemental-Tables-S1-S9.xlsx). No genes were identified as sig-
TABLE 1 Challenge participant demographics, clinical results, and preexisting antibody titers
Characteristica Value for characteristic
Mean age, yr (range) 27 (18–47)
Sex Male Female
No. of participants (%) 44 (53.0) 39 (47.0)
Race Asian Black White
No. of participants (%) 5 (6.0) 35 (41.7) 43 (51.1)
Group No MMID MMID
No. of participants 39 44
Mean max symptom score (range) 1.8 (0–7) 5.6 (1–14)
Mean no. of days of symptoms (range) 3.6 (0–34) 6.8 (2–11)
Mean no. of days of shedding (range) 0.15 (0–2) 3.7 (1–9)
Pre NAI titers (GMT) 258.5 47.7
Pre HAI titers (GMT) 22.4 4.2
Pre HA stalk titers (mean) 66,227 30,430
Quartile Lower quartile (Q1) Median quartile (Q2) Upper quartile (Q3)
Max symptom score 1 3 6
No. of days of symptoms 3 5 7.75
No. of days of shedding 0 1 4
Pre NAI titers (GMT) 80 160 320
Pre HAI titers (GMT) 0 10 80
Pre HA stalk titers (mean) 23,605.5 52,014.5 82,366.5
amax, maximum; Pre, preexisting (baseline).
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nificantly differentially expressed between shedders and nonshedders at 18 h postin-
fection. However, 151 genes were identified as significantly differentially expressed
(two-fold difference in median expression value, P value 0.05) between shedders and
nonshedders in at least one time point during the acute phase (42 h, 90 h, and 138 h
postinfection). These genes include molecular pattern and type I IFN response-related
genes (IFI27, TLR7, IFIT1-3, OASL, ISG15, IFI44, and OAS1-3), in addition to early TNFR
responses, such as TRAIL, observed at 42 h. The expression profiles of genes correlated
with viral shedding at 18 h, 42 h, 90 h, and 138 h are shown in Fig. S2A. Most viral
shedding-associated genes were increased relative to preexposure levels (Fig. S2A).
Consistent with a lack of significant differential expression at 18 h, a viral shedding gene
expression signature was not observed at this time point in shedding participants.
However, by 42 h postinfection, most shedders showed various levels of increased
expression of viral shedding-associated genes relative to the nonshedders, and
principal-component analysis using the 151 genes clearly showed participants group-
ing based on viral shedding status (Fig. 1A). A subset of shedders (n 7) showed either
very attenuated or no induction of viral shedding-associated gene expression signature
despite shedding virus for between 4 and 9 days, while other participants (n 4) not
shedding virus at day 2 showed increased expression of viral shedding-associated
genes at 42 h. Most of the nonshedding participants showing increased expression of
viral shedding-associated genes shed virus either on day 1 or later time points,
indicating that in some participants, the viral shedding-associated gene expression
signature is detected prior to or after viral shedding even in the absence of symptoms
(Fig. 1D).
Analysis of viral shedding-associated gene expression at 90 h and 138 h showed
similar trends at each of these time points. Most shedders showed increased expres-
sion, and principal-component analysis demonstrated grouping of participants based
on shedding status (Fig. 1B and C). However, participant subsets with discordant gene
expression were again observed at each time point in both the shedding and non-
shedding populations. In general, the participants without detectable viral shedding on
day 4 that exhibited increased expression of viral shedding-associated genes shed virus
either before or after the time point when increased expression of viral shedding-
associated genes was observed. This was particularly evident at 138 h where many
participants who were no longer shedding on day 6 still exhibited increased expression
of viral shedding-associated genes at 138 h, likely due to residual effects from active
viral shedding detected on prior days (Fig. S2A). Participants with active viral shedding
who did not show induction of viral shedding-associated genes typically lacked ex-
pression of viral shedding-associated genes only on a single day when viral shedding
was detected (Fig. S2B) but showed increased expression at later time points, suggest-
ing a delayed host response to infection. However, several participants showed no
induction of viral shedding associated at any time point during the acute phase of
infection despite shedding for multiple days (Fig. S2B).
Biological pathway classification of viral shedding-associated genes at 42 h
(n 151), 90 h (n 56), and 138 h (n 87) was performed using the Panther gene
ontology overrepresentation test (21, 22). Pathway activation was dominated by anti-
viral responses and stress responses, including interferon alpha/beta signaling, and
cytokine signaling (see Tables S1 to S3 at https://systemsbiology.org/wp-content/
uploads/Walters-et-al-Supplemental-Tables-S1-S9.xlsx). Responses limited to only 42 h
postinfection included TRAF3-dependent IRF activation, NF-B activation through the
FADD/RIP-1 pathway, TRAF6-mediated IRF7 and NF-B activation, as well as RIG-I/MDA5
activation (see Table S4 at the above URL). Collectively, these data demonstrate that a
PBL viral shedding-associated gene signature was present in most participants at time
points where IAV was present in nasal washes and in some participants prior to or
following viral shedding (Fig. 1D to F). However, there was a small subset of participants
who failed to initiate a host response despite multiple days of active viral replication.
PBL viral shedding-associated gene expression phenotype correlated with
clinical symptoms, length of viral shedding, and preexisting antibody titers. To
Walters et al. ®
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identify the factors driving phenotypic gene expression variation, unsupervised clus-
tering was used to group participants based on their PBL viral shedding associated
gene expression response independent of clinical parameters. At each time point
during acute infection, k-means clustering analysis identified three main subgroups of
participants based on the magnitude of their PBL viral shedding-associated gene
expression responses: (i) strong; (ii) variable, and (iii) no response (Fig. S3). As shown in
Fig. 2A, principal-component analysis was used to visualize participant grouping based
on viral shedding-associated gene expression at 42 h, and average expression levels of
viral shedding-associated genes were significantly different between the strong, vari-
able, and no response k-means phenotypes (Fig. 2B). Statistical analysis by rank sum t
test of clinical illness metrics, including maximum symptom score, number of days of
FIG 1 Viral shedding-associated PBL gene expression signature can be detected before and after detection of virus in nasal secretions. Principal-component
analysis (PCA) of active viral shedding-associated gene expression identified by two-tailed t test comparisons of transcripts whose expression levels differed
significantly (2-fold difference in median expression level, P value 0.05) in PBLs from participants with influenza virus-positive versus -negative nasal washes
at 42 h, 90 h, and 138 h after IAV challenge. Statistical tests were performed separately for each time point and identified 151 genes that were significant in
at least one time point. (A to C) PCA of viral shedding-associated gene expression at 42 h, 90 h, and 138 h postinfection showing viral shedding status at each
time point, respectively. Each participant is shown as a separate symbol with blue circles indicating participants not actively shedding virus and red plus symbols
indicate individuals with virus-positive nasal washes on that day. (D to F) Longitudinal viral shedding. PCA of viral shedding-associated gene expression at 42 h,
90 h, and 138 h postinfection, respectively, showing duration of shedding during the course of the study with the total number of days of viral shedding for
each participant indicated using a brown gradient with never shedding participants shown in blue.
Antibody Masking of Peripheral Blood Responses ®
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FIG 2 Differential PBL expression of viral shedding-associated gene expression at 42 h correlates with clinical symptoms, length of viral
shedding, and preexisting immunity. (A) Principal-component analysis of the three PBL viral shedding-associated gene expression response
(Continued on next page)
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symptoms, and duration of viral shedding was performed to determine whether the
three participant subgroups correlated with clinical outcome. The strong response
population at 42 h had significantly more severe illness and longer duration of illness
(median maximum symptom score 7.5; median 8 days symptoms) compared to
those with either variable (median maximum symptom score 2; median 5 days
symptoms) or no response (median maximum symptom score 2; median 3 days of
symptoms) (Fig. 2C and D). Participants with a strong PBL viral shedding-associated
gene expression response also shed virus for longer (median 5 days) than those with
either variable (median shedding 1 day) or no response (median shedding 0 days)
(Fig. 2E). Analysis of participant groups at 90 h and 138 h revealed similar statistically
significant differences in clinical disease (Fig. S4). Some participants with variable
response at 42 h also had significantly longer illness (median 5 days) compared to
those with no response (median 3 days) but were not significantly different in terms
of severity of illness or duration of shedding. No significant differences in clinical
metrics were observed between the variable and no response groups at 90 h and 138 h
postinfection (Fig. S4).
To examine the relationships between preexisting serum NAI, HAI, and HA stalk titer
and PBL gene expression responses, statistical analysis by rank sum t test of each
participant’s day 0 levels of serum antibodies directed against the viral NA by inhibition
titer (NAI), the HA head by inhibition titer (HAI), and the HA stalk domain by ELISA was
performed. Analysis of preexisting NAI titers showed that the participants in the 42 h
viral shedding-associated gene expression strong response group had a statistically
significant lower geometric mean titer (GMT) of 8.57 compared to the variable and no
response groups, with NAI GMTs of 236 and 112.6, respectively (Fig. 2F). No statistical
difference in NAI titer was observed between the variable and no response groups.
Analysis of day 0 HAI titers showed the 42 h strong response participants had statisti-
cally significant lower HAI titers with a group GMT of 2.37 compared to the variable and
no response groups that had HAI GMTs of 8.94 and 27.1, respectively (Fig. 2G).
Measurement of group I HA stalk antibody ELISA titer on day 0 similarly showed that
participants with a strong viral shedding-associated gene expression response at 42 h
had statistically significant lower HA stalk titers with a mean HA stalk antibody titer of
25,700 compared to the variable and no response participant groups, which had mean
titers of 63,867 and 81,176, respectively (Fig. 2H). Unlike NAI and HA stalk day 0 titer,
day 0 HAI titers were also significantly different between the variable and no response
groups, with a higher GMT seen in the no response compared with the variable
response group. Analysis of preexisting immunity on the 90 h and 138 h viral shedding-
associated gene expression phenotypes populations showed similar statistical differ-
ences in NAI, HAI, and HA stalk antibody titers between the viral shedding-associated
strong gene expression response group and the variable and no response participants
(Fig. S5). However, in contrast to 42 h, no statistical differences in HAI titer were
observed between the variable and no response groups at 90 h and 138 h (Fig. S5).
A longitudinal logistic regression model was also developed to determine which
gene expression changes were correlated with active viral shedding. This model
identified differential expression genes by fitting a mixed-effect model that included
gene expression, number of days, and age as covariates, and interaction terms between
gene expressions and days were considered (see Materials and Methods). Daily viral
shedding was used as the outcome variable, and its measurements over 4 days are
FIG 2 Legend (Continued)
groups at 42 h postinfection identified using k-means analysis. The three PBL viral shedding-associated gene expression response groups are
no response (blue), variable response (yellow), and strong response (red). (B) Graph of expression response group average expression of genes
associated with viral shedding at 42 h relative to day 0 (d0). (C to E) Statistical analysis of clinical illness, including maximum symptom score
(C), days of symptoms (D), and days of viral shedding (E) between the three PBL response groups. (F to H) Statistical analysis of preexisting
antibodies between PBL response groups as measured by day 0 NAI titer (F), HAI titer (G), and HA stalk ELISA titer (H). For NAI and HAI titers,
the geometric mean titer (GMT) is shown with 95% confidence intervals, while HA stalk titer is shown as the median titer with 95% confidence
intervals. Values that were statistically significant different for the different groups were assessed using rank sum t test and indicated by a bar
and asterisk as follows: *, P 0.05; **, P 0.01.
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modeled as longitudinal data. A list of 151 top-ranked genes was selected based on the
rankings of the model fitting results (see Table S5 at https://systemsbiology.org/wp
-content/uploads/Walters-et-al-Supplemental-Tables-S1-S9.xlsx). The decision to limit
this analysis to the top 151 logistic model ranked genes was made to allow for
comparison of clinical, immune, and response pathway classification with the 151 total
viral shedding-associated gene set. As shown in Fig. 3A and B, k-means analysis
grouped participants based on expression levels of logistic model identified genes into
strong, variable, and no response groups that showed significant differences in expres-
sion (Fig. S6). Increasing expression of logistic regression viral shedding-associated
genes also correlated with maximum symptom score, days of symptoms, and days of
shedding (Fig. 3C to E). These results were in agreement with the viral shedding-
associated genes shown in Fig. 2C to E.
Examination of preinfection (day 0) NAI, HAI, and HA stalk antibody titers in the
strong, variable, and no response participants at 42 h who showed strong expression
of the logistic regression viral shedding-associated genes had a significantly lower NAI
GMT of 7.56 compared to the variable and no response groups, with NAI GMTs of 230.4
and 158.4, respectively (Fig. 3F). No statistical difference in NAI titer between the
variable and no response groups was observed. As shown in Fig. 3G, at 42 h, HAI GMT
titers in the strong logistic regression viral shedding-associated gene response group
(2.25) were significantly lower than both the variable and no response groups (GMT of
9.24 and 26.61, respectively). The HAI titer in the logistic regression viral shedding-
associated variable gene expression response group was also significantly lower than
the no response group. Comparison of baseline group I HA stalk antibody titer also
demonstrated that participants in the 42 h strong response group expression group
had significantly lower HA stalk titers, with a median HA stalk antibody titer of 17,774,
compared to the variable and no response participant groups, with median titers of
50,912 and 63,949, respectively (Fig. 3H). Analysis of preexisting NAI and HA stalk based
immunity at 90 h and 138 h in the logistic regression viral shedding-associated strong
gene expression groups showed statistical differences with variable and no response
participants like those observed for viral shedding-associated gene expression (Fig. S7).
Analysis of HAI titers in the response group at 90 h showed significantly lower HAI titer
in the strong response group compared to the no response group, while HAI titers of
the strong logistic regression viral shedding response group at 138 h was significantly
lower than the both the variable and no response groups. These results both confirmed
the importance of preexisting NA and HA stalk antibody correlation results show in
Fig. 2F and G. Taken together, the clinical disease and immune correlates of logistic
regression viral shedding-associated gene expression were nearly identical to the
results described for expression of daily t test-derived viral shedding-associated genes
shown in Fig. 2. Comparison of viral shedding-associated genes derived from t test and
logistic regression showed an 80.1% overlap of genes with nearly identical pathway
classification results (see Table S6 at https://systemsbiology.org/wp-content/uploads/
Walters-et-al-Supplemental-Tables-S1-S9.xlsx).
PBL expression signatures predictive of length of viral shedding and differen-
tial role of HA stalk antibodies. In most participants, onset of detectable viral
shedding in nasal wash samples was 18 h postchallenge (31/44 MMID participants and
4/4 of the No MMID participants that asymptomatically shed virus), although in some
participants, it was delayed for up to 4 to 5 days (Fig. S8A). As shown in Fig. 4A, duration
of viral shedding was highly variable, ranging from 1 to 9 days in the MMID population
and 1 to 3 days in the No MMID population. The total number of days of viral shedding
in nasal passages of each participant was used as a reference to identify genes whose
expression level correlated with how long an individual was potentially contagious. The
goal was to identify genes detectable between 42 h and 90 h that could predict
duration of viral shedding to help limit spread of infection. Pearson correlation analysis
(r 0.5) identified 229 and 177 genes with expression levels that positively correlated
with length of shedding at 42 h and 90 h, respectively, with 125 genes common
between the two time points. No genes that negatively correlated with length of
Walters et al. ®
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FIG 3 Logistic regression determined differential PBL gene expression correlated with viral shedding. (A) Principal-component analysis of
participant PBL expression of viral shedding-associated genes identified by logistic regression at 42 h postchallenge. The response group was
(Continued on next page)
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shedding were identified. Higher expression of these length of shedding-correlated
genes (n 125) correlated with quartile of shedding (Table 1), as shown in Fig. 4B and
C. Statistical analysis demonstrated significant differences in expression levels of length
of shedding-correlated genes at 42 h postinfection, with participants in the upper
quartile of shedding showing the highest expression (Fig. 4D). In a hospital/clinical
setting, individual preexposure samples would not be available for use as a baseline. To
determine whether the length of shedding signature could also be used to predict
duration of shedding in the absence of individual baselines, a pool of the entire cohort’s
(n 83) baseline prechallenge expression was instead used as the baseline to deter-
mine length of shedding-correlated gene expression levels at 42 h and showed similar
results (Fig. S8B and C).
Analysis of NA, HA head, and HA-S antibodies in participants grouped by quartile of
length of nasal wash viral shedding demonstrated that NAI titers were significantly
lower in participants with the highest quartile of viral shedding with a GMT of 15.3
compared to both median and lowest quartile shedders with GMTs of 188.8 and 288.1,
respectively (Fig. 4E). Analysis of HAI titer showed that the highest quartile shedders
had significantly lower titers (GMT 3.1) compared to the lowest quartile shedders
with (GMT 29.8), while median quartile shedders had significantly lower HAI titer
compared to the lowest quartile shedders (GMT 6.65) (Fig. 4F). Comparison of
preexisting HA stalk antibodies revealed a statistical difference between all three
quartiles of length of shedding, as shown in Fig. 4G. Participants in the highest quartile
for shedding had a HA stalk mean titer of 30,245 compared to those in the middle
quartile with a mean titer of 57,929 and the lowest quartile shedders with a mean titer
of 87,747. A subset of participants in the highest quartile of shedding group showed no
or little change in expression level of the length of shedding signature (Fig. 5C). Unlike
most participants in the highest quartile of shedding, these participants generally had
higher levels of at least one antibody directed against NA, HA, or HA stalk (Fig. S9).
PBL expression signatures predictive of illness severity. Although the onset of
symptoms was day 1 for most participants, peak illness, defined by the maximum
symptom score during each participant’s course of illness, occurred between days 3
and 4 postinfection in both MMID and No MMID populations (Fig. S10A and B), with the
MMID participants reporting markedly higher daily symptom scores (Fig. 5A and B). Day
3 postinfection was the most common time point when MMID participants experienced
their peak illness (n 14). Among the No MMID population, day 3 was also the most
common day for peak illness (n 11). However, in contrast to the MMID population, a
greater proportion of the No MMID participants exhibited their highest symptoms
scores on days 1 and 2 (n 4 and n 7, respectively), suggesting that peak illness
occurs earlier in the No MMID population. While the kinetics of symptom onset and
peak illness was consistent within the MMID population, the severity of illness varied
considerably, as shown in both the range in daily reported symptoms and the maxi-
mum symptom score for participants (Fig. 5A), while both the range and maximum
symptom scores were markedly smaller in the No MMID population (Fig. 5B).
Given the range in disease severity following IAV exposure, the ability to triage
patients during acute infection and identify those at risk of progressing to severe illness
could decrease morbidity/mortality associated with influenza complications. To accom-
plish this, the maximum symptom score was used as a reference to identify genes
whose expression level correlated with a participant’s disease severity. Correlation
analysis (r 0.5) identified 145 and 196 genes with expression levels that positively
FIG 3 Legend (Continued)
determined by k-means analysis: no response (blue), strong response (red), and variable response (yellow). (B) Graph of response group average
gene expression at 42 h genes relative to day 0. (C to E) Statistical analysis of clinical illness, including maximum symptom score (C), days of
symptoms (D), and days of viral shedding (E) between the 42 h PBL expression response groups. (F to H) Statistical analysis of preexisting
antibodies between the three PBL response groups at 42 h postinfection as measured by day 0 NAI titer (F), HAI titer (G), and HA stalk ELISA titer
(H). For NAI and HAI titers, the geometric mean titer (GMT) is shown with 95% confidence intervals, while HA stalk titer is shown as median with
95% confidence intervals. Statistical significance between groups was assessed using rank sum t test and indicated as follows: *, P 0.05; **,
P 0.01.
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FIG 4 PBL expression signatures present at 42 h correlate with length of viral shedding. (A) Graph showing length of shedding in days in mild-to-moderate
influenza disease (MMID) and No MMID participants. (B) Heatmap showing postinfection expression profiles of transcripts (n 125) at 42 h postinfection that
correlate (r 0.5) positively with length of shedding in participants grouped by quartile of length of shedding. Genes shown in green to red were increased
and genes shown in blue to black were decreased relative to each participant’s day 0 expression. (C) Principal-component analysis of length of shedding
correlated genes at 42 h postinfection colored by quartile of length of shedding (Table 1). (D) Graph of the average 42 h expression of length of shedding
correlated genes relative to day 0 grouped by quartile of length of shedding. (E to G) Statistical analysis of preexisting antibodies between participants grouped
by quartile of length of shedding as measured by day 0 NAI titer (E), HAI titer (F), and HA stalk ELISA titer (G). Statistical significance between groups was
assessed using rank sum t test with t test and indicated as follows: *, P 0.05; **, P 0.01.
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FIG 5 PBL expression signatures present at 42 h correlated with later disease severity. (A and B) Box plot of range of daily symptom scores in participants with
mild-to-moderate influenza disease (MMID) (A) and participants with No MMID (B). (C) Heatmap showing expression profiles of transcripts (n 126) at 42 h
postinfection that correlate (r 0.5) positively with maximum symptom score. Genes shown in green to red were increased and genes shown in blue to black were
decreased relative to each participant’s day 0 expression. (D) Principal-component analysis of maximum symptom-correlated genes at 42 h postinfection colored by
quartile of maximum symptom score. (E) Graph of average 42 h expression of maximum symptom-correlated genes relative to day 0 grouped by quartile of maximum
symptom score. (F to H) Statistical analysis of preexisting antibodies between participants grouped by quartile of maximum symptom score as measured by day 0 NAI
titer (F), HAI titer (G), and HA stalk ELISA titer (H). Statistical significance between groupswas assessed using rank sum t test and indicated as follows: *, P0.05; **, P0.01.
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correlated with maximum symptom scores using expression data from 42 h and 90 h,
respectively, with 126 genes common between the two time points. No genes that
negatively correlated with maximum symptom score were identified. As shown in
Fig. 5C and D, expression levels of these 126 genes at 42 h correlated with the quartile
of overall maximum symptom score, with statistically higher average expression of
these genes in participants in the top quartile of maximum symptom score (Fig. 5E),
even though at 42 h, most had not yet reached peak illness. Again, the maximum
symptom signature was assessed using a pool of the entire cohort’s day 0 (n 83) as
the reference baseline to determine expression levels of the maximum symptom-
correlated genes (Fig. S10C and D).
Analysis of preexisting NA antibodies in participants grouped by quartile of maxi-
mum symptom score (Fig. 5F) showed that expression of these genes also correlated
with significantly lower NAI titer in participants in the highest quartile of maximum
symptom score (GMT 22.3) compared to both median and lowest quartile partici-
pants with NAI GMTs of 168 and 259, respectively. No statistical difference in NAI was
observed between median and lowest quartile maximum symptom score participants.
PBL expression of maximum symptom-correlated genes also correlated with preexist-
ing HA head antibodies (Fig. 5G), with participants in the top quartile of maximum
symptom score having the statistically significant lowest titers (HAI GMT 3.2) com-
pared to participants with median and lowest quartile maximum symptom scores with
HAI GMT of 13.3 and 169.1, respectively. No statistical difference in HAI titer was
observed between the median and lowest quartile maximum symptom score partici-
pants. Analysis of preexisting HA stalk antibody titers showed statistically lower titers in
participants in the top quartile of maximum symptom scores (mean titer  39,394)
compared to the median and lowest quartile participants (mean titers of 68,406 and
72,801, respectively) (Fig. 5H). No difference in serum HA stalk antibody titer was
observed between lowest and median quartiles. Pathway classification analysis of the
length of shedding and maximum symptom-correlated gene sets showed nearly
identical results (see Tables S7 and S8 at https://systemsbiology.org/wp-content/
uploads/Walters-et-al-Supplemental-Tables-S1-S9.xlsx), with TRAF3-dependent IRF ac-
tivation mapped only to the maximum symptom-correlated genes (see Table S9 at the
above URL).
DISCUSSION
The present study was designed to correlate clinical outcome and preexisting NA
and HA antibody titers with PBL transcriptional responses in influenza A virus-infected
participants with a wide range of preexisting serum antibody titers to NA, HA head, and
HA stalk. Expression analysis showed unique and common populations of genes that
were correlated with a positive clinical microbiology test for viral shedding in nasal
washes on days 2, 4, and 6 postinfection. k-means clustering analysis of the active viral
shedding genes showed three main PBL gene expression phenotypes, with some
participants showing a “strong” expression phenotype, while others had a “variable
response” or “no response.” The PBL expression phenotype of viral shedding-associated
genes after viral infection was not predicated by day 0 PBL expression values but
instead was correlated with preexisting serum antibody titers against NA, HA head, and
HA stalk. While preexisting NA, HA head, and HA stalk antibody titers all correlated
significantly with PBL viral shedding-associated gene expression phenotype, maximum
clinical symptom score, and days of symptoms and days of shedding, only HA head
antibody titer (as measured by HAI) was shown to be statistically significant between
variable and no response participant groups at 42 h postinfection. We were further able
to identify populations of genes that were correlated with and were predictive of
length of viral shedding and illness severity (as measured by maximum symptom
score).
Previous studies have examined PBL transcriptional profiling following IAV chal-
lenge to identify host-based prognostic and diagnostic markers (23, 24). One study
examining whole-blood mRNA signatures in a large cohort of adults hospitalized with
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confirmed influenza infection found that interferon-related signatures were generally
associated with less severe infection, while bacterial response-related signatures were
associated with more severe infection (requiring mechanical ventilation) (25). Woods et
al., performed transcriptional profiling on peripheral blood samples from 41 healthy
volunteers experimentally challenged with H1N1 or H3N2 IAV, 18 of whom developed
symptomatic infection (defined as a modified Jackson score of 6 for 5 consecutive
days plus viral shedding for at least 2 consecutive days), and a gene expression
signature was identified in these challenge participants that could detect the majority
of infected cases (23). Using the same cohort of H3N2 IAV-challenged participants,
biomarker signatures distinguishing early from later phases of infection were identified
(26). However, these studies included only participants without detectable baseline HA
head antibody titers and antibodies to NA and HA stalk were not measured, so it is
unclear how preexisting immunity would affect detection of these biomarker signa-
tures. An important finding of the current study is that the analysis of peripheral blood,
which is distal to the site of infection, for influenza diagnostic/prognostic testing is
affected by preexisting immunity with antibody titers adequate to suppress PBL gene
expression responses but insufficient to prevent viral shedding and symptoms (see
Fig. S9 in the supplemental material). This masking of gene expression biomarkers will
reduce the predictive accuracy of point-of-care devices. While clinical symptoms, such
as disease severity and presence of pneumonia, and demographic data, such as age
and presence of comorbidities, are correlates of length of shedding (27–31), many of
these clinical disease correlates of medically attended influenza do not manifest until
many days after infection and have limited prognostic value. In contrast, significant
differential PBL gene expression can be observed before 48 h postexposure just as
symptoms are beginning to appear. Thus, the development of PBL gene expression-
based disease prediction currently has its greatest clinical potential during outbreaks or
pandemics where little protective immunity is present in the population.
The dominant influenza virus surface antigens are NA and HA proteins (1). In
addition to targeting immune cell responses, such as opsonization and antibody-
dependent cellular phagocytosis (ADCP), complement-mediated cytotoxicity (CMC),
and antibody-dependent cell-mediated cytotoxicity (ADCC), antibodies can also directly
inhibit viral protein function (32, 33). Antibodies against the head region of HA, which
contains the receptor binding domain (RBD), are neutralizing both in vitro and in vivo,
and antibodies directed against the HA stalk region have been shown to be more
broadly protective and can be neutralizing both in vitro and in vivo (17, 34, 35). HA head
immunity has also been shown to be an independent predictor of MMID and viral
shedding, but not symptom severity, and HA stalk immunity was an independent
predictor only of MMID (11). Clinical studies have shown that NA immunity is an
independent predictor of MMID (i.e., shedding with symptoms), viral shedding, and
symptom severity. Further, vaccination with recombinant NA proteins has shown
potent clinical efficacy, and increasing NA antibody responses remain an attractive
target for vaccine development (17, 34, 35, 36, 51). Of the three antibody titers
measured in this study, HA head immunity was shown to be the most effective
antibody correlate of differential PBL gene expression as a predictor of both length of
shedding and number of symptoms, which is likely attributable to the potent neutral-
izing ability of HA head antibodies.
Many of the gene expression signatures for viral shedding, length of shedding, and
maximum symptom consisted of genes associated with elevated antiviral responses,
notably type I IFN responses, consistent with a recent report associating strong
induction of antiviral response-related gene signatures in patients with less severe
influenza infection (25). In the current study, several antiviral pathways, including
pathogen-associated molecular pattern (PAMP) receptor responses, including both TLR
and RIG-I (DDX58) signaling responses, as well as TNF receptor superfamily responses,
were observed only early in infection (by 42 h postinoculation), namely, the strong
induction of genes in the TNFRSF signaling pathway early in infection, including
increased expression of IRF7 and NF-B activation downstream of TRAF3/6 signaling
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from TNFRSF members, as well as significantly increased expression of TNFSF10 (TRAIL)
in participants with active viral shedding. TRAIL can interact with several TNFRSF
members, which results in the activation of MAPK8/JNK, and CASP3/8. Death receptor
interaction with TRAIL has been reported to lead to death domain (DD)-mediated
interaction with FADD and activation of the death effector domain (DED) or FADD
(37–39). Activated natural killer (NK) cells and CD8 cells have been reported to express
both TRAIL and cognate receptors, although they themselves have been shown to be
resistant to the cytotoxic effect of TRAIL (40). The role of TRAIL in early PBL responses
to influenza infection is unclear, nor is it clear whether these signals originate in the PBL
NK and CD8 T cells or from the respiratory epithelium where infection is occurring,
and additional studies will be needed to address the roles of these observations in
clinical disease.
The ability to predict IAV contagiousness and illness severity through examination
of PBL gene expression responses and subsequent development of point-of-care
diagnostic/prognostic assays is an important goal that could have significant impact on
public health, particularly regarding patient triage, isolation, drug treatment, and
medical intervention (including mechanical ventilation and antivirals or initiation of
antibiotics for secondary bacterial pneumonias) during an epidemic or pandemic (41),
but the question of how PBL and serum antibody responses relate to influenza virus
infection of upper respiratory tract epithelial cells remains unanswered. The strongest
gene expression responses observed in this study were present in PBLs from challenge
participants with the longest length of shedding and most severe symptoms; however,
several participants (7 of 83) were symptomatic shedders but did not show an elevated
PBL gene expression response. An explanation for this observation is that increased
disease is associated with a larger antiviral response in the respiratory epithelium with
higher concentrations of antiviral cytokines (e.g., type I IFNs) that leads to a “spillover”
effect into the peripheral blood. It would be expected that participants with disease
that lacked a PBL signal were mounting antiviral and immune responses in the
nasopharynx arising from infection of nasal epithelial cells. Examination of mucosal
immune responses, including characterization of epithelial (42, 43) and resident im-
mune cell responses, measurement of antibodies (including secreted IgA) and antiviral
and immune mediators in nasal epithelial and airway samples will be particularly
important to understand the relationships between respiratory and peripheral cellular
responses. Moreover, characterization of responses in different immune cell popula-
tions (44), the relationships between antibody responses and cellular immunity (45),
and how influenza exposure history (from vaccination and/or natural infection) affects
antibody and T cell receptor repertoires (46) in challenge studies and community-
acquired infection cohorts will be critical for the understanding of clinical disease and
for vaccine development and testing.
MATERIALS AND METHODS
Clinical study. Two healthy volunteer wild-type (H1N1)pdm09 influenza challenge studies were
performed at the National Institutes of Health (NIH) Clinical Center, as previously described (12, 19).
Briefly, healthy volunteers (ages ranged from 18 to 50 years) were intranasally inoculated with 107 50%
tissue culture infective doses (TCID50) of a GMP-manufactured wild-type 2009 influenza A (H1N1)pdm
virus. Daily viral shedding in nasal wash samples was determined using the BioFire FilmArray multiplex
respiratory pathogen assay (19, 47). Daily clinical symptoms were documented by both physician- and
patient self-assessment and included nasal/sinus congestion, fatigue, headache, rhinorrhea, sore throat,
myalgia, dry cough, productive cough, arthralgia, chills, diarrhea, nausea, fever (38°C), and sweats as
described in reference 19. PBLs were collected for RNA extraction and expression microarray analysis
immediately before inoculation and then at 18 h, 42 h, 90 h, and 138 h after infection. Multiple clinical
endpoints were reported including the presence or absence of mild to moderate influenza disease
(MMID), defined as a positive molecular clinical test for influenza plus symptoms. In addition, symptom
severity (defined as the number of influenza-related symptoms), presence or absence of symptoms or
shedding alone, duration of symptoms, and duration of shedding were recorded. The studies (clinical-
trials.gov identifier NCT01971255 and NCT01646138) were approved by the NIAID Institutional Review
Board and conducted in accordance with the provisions of the Declaration of Helsinki and good clinical
practice guidelines.
Measurement of serum anti-HA, anti-HA head, and anti-HA stalk antibodies. Measurements of
neuraminidase inhibition (NAI), hemagglutination inhibition (HAI), and viral shedding used for this
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analysis were detailed previously and used standard methods (11). Measurement of antihemagglutinin
(anti-HA) stalk antibody titers were using an enzyme-linked immunosorbent assay (ELISA) method as
previously described (11).
RNA isolation and expression microarray analysis. Total RNA was isolated from whole blood using
PAXgene Blood RNA kit IVD (Qiagen, Gaithersburg, MD). RNA quality was assessed using a BioAnalyzer
(Agilent Technologies, CA). Gene expression profiling experiments were performed using Agilent Human
Whole Genome 44K microarrays. Fluorescent probes were prepared using Agilent QuickAmp labeling kit
according to the manufacturer’s instructions. Each RNA sample was labeled and hybridized to individual
arrays. Spot quantitation was performed using Agilent’s Feature Extractor software, and all data were
then entered into a custom-designed database, SLIMarray (http://slimarray.systemsbiology.net), and then
uploaded into Genedata Analyst 9.0 (Genedata, Basel, Switzerland).
Statistics. Data normalization was performed in Genedata Analyst using central tendency, followed
by relative normalization using each individual participant’s baseline (day 0) as a reference or using
pooled day 0 data (n 83). Pearson correlation, Student’s t test, k-means and principal-component
analyses were performed using Genedata Analyst 9.0 and GraphPad Prism. All statistical analysis was
performed using individual replicates, and the Benjamini-Hochberg procedure was used to correct for
the false-positive rate in multiple comparisons. For immunity correlation analysis, a rank sum t test was
performed using R. Panther (21, 48) was used for gene ontology and Reactome pathway analysis using
Bonferroni correction. A longitudinal logistic regression was also used to model and rank genes that best
explain the variations in the daily viral shedding (as determined by BioFire assay positivity). Briefly, we
model the daily binary viral shedding indicator using a logistic model with age, time, and gene as
covariates and a subject-specific random intercept term ui to addresses the correlation among multiple
measurements. Let the response yij denote the daily BioFire assay positivity at the jth day for subject i,
the longitudinal logistic regression model is described as follows:
log[Eyij|X)]  ui 1Agei 2Timeij 3Timeij2  4Geneij 5Geneij	 Timej 6Geneij
	 Timej
2
Marginal (regression) screening was used to determine which dependent variables (differentially ex-
pressed genes) were correlated with the PBL gene expression response. A random intercept term was
used to address the correlation among different measures of the same subjects. This model was applied
to each gene separately and recorded the 2 log likelihood as the model fitting result. After ranking the
genes, we selected the top 151 genes. This number of genes was chosen to match the total number of
genes identified by t test correlation of daily PBL gene expression with daily viral shedding.
Data availability. The complete MIAME-compliant (49) microarray data set has been deposited in
NCBI’s Gene Expression Omnibus (50) and is accessible through GEO Series accession number
GSE118223.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00760-19.
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